Search results
Showing 121 to 135 of 169 results for asthma
This guideline sets out an antimicrobial prescribing strategy for acute otitis media (ear infection). It aims to limit antibiotic use and reduce antimicrobial resistance. Acute otitis media can be caused by viruses or bacteria. It lasts for about a week, and most children get better in 3 days without antibiotics. Serious complications are rare.
Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)
Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir or Symmetrel) or zanamivir (Relenza) to prevent influenza (flu).
Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)
Evidence-based recommendations on amantadine (Lysovir), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza in children and adults.
Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.
This guidance has been updated and replaced by NICE indicator 273.
This guidance has been updated and replaced by NICE indicator 272.
This evidence summary has been updated and replaced by NICE guideline NG80.
This guidance has been updated and replaced by NICE interventional procedures guidance 635.
We have moved interventional procedures guidance 635 to become HealthTech guidance 494. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)
Evidence-based recommendations on budesonide as an orodispersible tablet for inducing remission of eosinophilic oesophagitis in adults.
NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .
This guidance has been replaced by NICE technology appraisal guidance 278.
Asthma: fluticasone/formoterol (Flutiform) combination inhaler (ESNM3)
This evidence summary has been updated and replaced by NICE guideline NG80.
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.
New hope for people with breathing condition, COPD, as NICE approves innovative treatment
Breakthrough therapy reduces flare-ups by almost a third and could ease pressure on NHS hospitals.